We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Mounjaro
Update on the use of Tirzepatide (Mounjaro) for managing overweight and obesity.
NHS Kent and Medway has issued an update on the implementation of the National Institute for Health and Care Excellence (NICE) technology appraisal TA 1026: Tirzepatide for managing overweight and obesity.
It clarifies that, currently, there should be no prescribing of Mounjaro (tirzepatide) for managing overweight and obesity (NICE TA 1026) in primary care. Please note, this does not affect those patients suitable for Mounjaro (tirezepatide) in line with NICE guidance on tirzepatide for treating type 2 diabetes (NICE TA 924).
Published: Mar 10, 2025